Introduction: Hirsutism is a condition of unwanted malepattern hair growth in women. Perception of hirsutism is subjective and it is a common condition affecting 5-10% of unselected women. Objectives: To find out the efficacy and safety of long-pulsed Nd-YAG laser in the treatment of hirsutism. Materials and Methods: Fifty females of age between 18- 50 years with dark terminal facial hair and normal hormonal profile were treated with long-pulsed Nd-YAG laser (1064nm, 10mm spot size, pulse duration of 25-30 minutes and fluence of 25-40J/cm2). Six consecutive sessions of laser treatment were delivered to all the patients at 4 to 6 weeks’ interval. Photographic evaluations and percentage of hair reduction were done before each session and final assessment noted at the end ofninemonths. Results: All the patients completed the study. Good hair reduction (50-75%) was seen in 52% of patients after the first treatment session. After six consecutive treatment sessions at the end of nine-month excellent hair reduction (>75%) was noted in 86% of patients and good hair reduction (50-75%) seen in 12% patients. Side effects in our study were post-operative erythema in 40% and perifollicular oedema in 33.33%. Conclusion: The study supportslong-pulsed Nd-YAG laser with multiple six sessionsis safe and effective in the treatment of hirsutism. Journal of Armed Forces Medical College Bangladesh Vol.14 (2) 2018: 169-172

Introduction: Atopic dermatitis is a recurrent inflammatory skin disease with intense pruritus as its hallmark symptom. It often follows a chronic, relapsing course. Objectives: This comparative study was done with an aim to find out the efficacy of Tacrolimus and Hydrocortisone acetate in 2-5 year old children with Atopic dermatitis. Methods: This clinical trial was carried out on two equal groups of 60 patients. “Group A” was treated with topical tacrolimus ointment (0.03%) and “group B” with hydrocortisone acetate ointment (1%). Follow up was done at week 1, 2, 4, 8 and 12 of treatment for assessment of improvement and adverse event, which was measured by ‘overall clinical improvement in the physician's global evaluation of clinical response’. Data was collected in a predesigned data collection sheet, and analysis was performed by SPSS program (Version 12). Results: Excellent, marked and moderate improvement were observed in 19 (63.3%), 9 (30.0%), and 2(6.7%) patients of tacrolimus group and 1(3.3%), 2(6.7%) and 27(90.0%) patients of hydrocortisone group respectively. Tacrolimus group had significantly better improvement than hydrocortisone group (p<0.001). Skins burning at application site were observed significantly more in tacrolimus group 8(26.7%) than in hydrocortisone group 2 (6.7%). 53 JAFMC Bangladesh. Vol 10, No 1 (June) 2014 Conclusion: The study showed tacrolimus ointment is more effective than hydrocortisone acetate in the treatment of atopic dermatitis in paediatric patients. DOI: http://dx.doi.org/10.3329/jafmc.v10i1.22924 Journal of Armed Forces Medical College Bangladesh Vol.10(1) 2014

Introduction: Psoriasis is a common, chronic, inflammatory and proliferative disease of the skin, also affecting nail and joints. Although there are a range of treatment options available, none have proved to wane the symptoms fully and also they reappear in course of time. Aim: To explore the safety and efficacy of Apremilast and Methotrexate on chronic plaque psoriasis patients. Methods: A randomized open clinical trial was done among fifty clinically diagnosed chronic plaque psoriasis patients in the Department of Dermatology and Venereology at Combined Military Hospital (CMH), Dhaka from 1st July 2017 to 30th June 2018. Patients were divided randomly into two equal treatment groups, 25 for Methotrexate and 25 for Apremilast. Involvement of body surface by plaque psoriasis, erythema, scaling and induration were recorded in a 3 points scale before treatment and 8 weeks after starting the treatment and finally at 12th week. Results: Reduction of psoriasis at 1st follow up in Methotrexate and Apremilast groups were 29.9±9.0 and 31.9±11.6 respectively and at 2nd follow up were 85.9±7.3 and 28.48±39.3 respectively. Significantly higher improvements were observed in Methotrexate group than Apremilast group both at 1st and 2nd follow up (p=0.001). Conclusion: Methotrexate is a better therapeutic option than Apremilast in the treatment of chronic plaque psoriasis. JAFMC Bangladesh. Vol 15, No 1 (June) 2020: 39-41